Pooled CRISPRi screening reveals fungal-specific vulnerabilities across environments and genetic backgrounds
The rising rate of drug-resistant fungal infections and the emergence of fungal pathogens with intrinsic resistance phenotypes are a growing concern. The close evolutionary distance between mammals and fungi complicates the design of new antifungals and increases the chances of toxic off-target effects. As such, antifungal drug development usually focuses on fungal-specific proteins when considering potential new targets. Ideal drug targets should mediate essential cell processes and be highly sensitive to inhibition. Targeted gene repression can serve as a model for drug-mediated inhibition and for determining the dosage-sensitivity profile of genes of interest. In the fungal pathogen <i>Candida albicans</i>, classical approaches for gene repression can be labour-intensive and limited to one genetic background due to low throughput. Here, we adapt pooled CRISPRi screening in <i>C. albicans</i> for the first time and exploit this technique for large-scale functional genomic analysis. Through pooled CRISPRi screening, we test the repression sensitivity of over a hundred essential genes conserved in fungi but absent in humans, and successfully identify highly dosage-sensitive genes across multiple cell components and pathways. By extending our analysis to ten diverse environmental conditions, we show how the environment influences dosage-sensitivity profiles. Finally, we extend our experiments to two clinical drug-resistant <i>C. albicans</i> strain backgrounds and demonstrate that many of the fitness defects we observed are conserved in resistant clinical isolates. Together, our results highlight a set of genes that are highly dosage-sensitive across different genetic and environmental contexts, making them attractive targets for further investigation. By facilitating rapid, efficient large-scale functional genomics assays across diverse genetic backgrounds, CRISPRi pooled screening will open new frontiers in <i>C. albicans</i> biology.
Authors
- Christina A. Cuomo (ORCID: https://orcid.org/0000-0002-5778-960X)
- Nicholas C Gervais (ORCID: https://orcid.org/0000-0002-9971-0031)
- Aleeza C. Gerstein (ORCID: https://orcid.org/0000-0002-0781-9356)
- Philippe C Després (ORCID: https://orcid.org/0000-0003-1407-0643)
- Meea Fogal (ORCID: https://orcid.org/0000-0002-0483-9626)
- Lauren Wensing (ORCID: https://orcid.org/0000-0003-3737-5474)
- Abdul-Rahman Adamu Bukari (ORCID: https://orcid.org/0000-0002-0923-3893)
- Rebecca S. Shapiro (ORCID: https://orcid.org/0000-0002-7119-8865)
- Clara Fikry
- Desiree Francis
- Anthony Hendriks
Institutions
- Broad Institute (US)
- Brown University (US)
- University of Manitoba (CA)
- University of Guelph (CA)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2025-12-22
- DOI
- https://doi.org/10.64898/2025.12.19.695556
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Alliance de recherche numérique du Canada
- Canadian Institutes of Health Research
- Fonds de Recherche du Québec - Santé
- National Institute of Allergy and Infectious Diseases